摘要
[Objectives]This study aimed to investigate the inhibiting effect of Obazema on proliferation of gastric cancer BGC-823 cells and its mechanism.[Methods]BGC-823 cells were treated with high,medium and low concentrations of drug-containing serum(0.316%,0.158%and 0.079%)for 0,48,72 and 96 h,respectively.Then,the proliferation of the cells was detected with CCK-8 method,and the expression of related proteins,B lymphocytoma-2(Bcl-2),phosphorylated protein kinase B(p-Akt),protein kinase B(Akt)and glyceraldehyde-3-phosphate dehydrogenase(GAPDH),was detected using Western blotting.[Results]The proliferation of the BGC-823 cells was significantly inhibited with different doses of Boenninghausenia albiflora(Hook.)Reichb.ex Meisn.var.albiflora(CH)and B.sessilicarpa Lévl.(S)(P<0.01),in dose-dependent and time-dependent manners.The inhibition of high-dose S on cell proliferation was similar to that of CTX 48 h after administration;the inhibition of high-dose CH on cell proliferation was significantly stronger than that of CTX(P<0.01);different doses of drug administration groups significantly inhibited the expression of p-Akt and Bcl-2 in the BGC-823 cells;the inhibition of high-dose CH on the expression of P-Akt and Bcl-2 and the inhibition of medium-dose CH on the expression of Bcl-2 were significantly stronger than that of CTX(P<0.05,P<0.01),in a certain dose-dependent manner;at the same dose,the inhibition of CH on the expression of the proteins was stronger than that of S(P<0.05,P<0.01);administration of S and CH significantly inhibited the expression of GAPDH compared with CTX(P<0.05,P<0.01).[Conclusions]Obazema has the capacity to inhibit the proliferation of BGC-823 cells.The mechanism may be achieved by inhibiting the expression of p-Akt and Bcl-2,and GAPDH may be the target gene of its anti-tumor mechanism.The inhibiting effect of CH on BGC-823 cells was more significantly than that of S.
[Objectives] This study aimed to investigate the inhibiting effect of Obazema on proliferation of gastric cancer BGC-823 cells and its mechanism. [Methods] BGC-823 cells were treated with high, medium and low concentrations of drug-containing serum(0.316%, 0.158% and 0.079%) for 0, 48, 72 and 96 h, respectively. Then, the proliferation of the cells was detected with CCK-8 method, and the expression of related proteins, B lymphocytoma-2(Bcl-2), phosphorylated protein kinase B(p-Akt), protein kinase B(Akt) and glyceraldehyde-3-phosphate dehydrogenase(GAPDH), was detected using Western blotting. [Results] The proliferation of the BGC-823 cells was significantly inhibited with different doses of Boenninghausenia albiflora(Hook.) Reichb. ex Meisn. var. albiflora(CH) and B. sessilicarpa Lévl.(S)(P<0.01), in dose-dependent and time-dependent manners. The inhibition of high-dose S on cell proliferation was similar to that of CTX 48 h after administration; the inhibition of high-dose CH on cell proliferation was significantly stronger than that of CTX(P<0.01); different doses of drug administration groups significantly inhibited the expression of p-Akt and Bcl-2 in the BGC-823 cells; the inhibition of high-dose CH on the expression of P-Akt and Bcl-2 and the inhibition of medium-dose CH on the expression of Bcl-2 were significantly stronger than that of CTX(P<0.05, P<0.01), in a certain dose-dependent manner; at the same dose, the inhibition of CH on the expression of the proteins was stronger than that of S(P<0.05, P<0.01); administration of S and CH significantly inhibited the expression of GAPDH compared with CTX(P<0.05, P<0.01). [Conclusions] Obazema has the capacity to inhibit the proliferation of BGC-823 cells. The mechanism may be achieved by inhibiting the expression of p-Akt and Bcl-2, and GAPDH may be the target gene of its anti-tumor mechanism. The inhibiting effect of CH on BGC-823 cells was more significantly than that of S.
基金
Supported by National Key Technology Research and Development Program(2018FYC1708000)
Basic Research Project for Application of Science and Technology in Sichuan Province(2017JY0274)
Science and Technology Research Project of Sichuan Traditional Chinese Medicine Administration(2018JC028).
